Skip to Main Content
Our Commitment to Diversity

COVID-19: FDA Warning Letters Address Fraudulent Products and Failures to Meet EUA Requirements

Share via LinkedIn
Share via Twitter
Share via Facebook
Date: 12 November 2020
Triage

In this week’s episode, Kenneth Kennedy discusses FDA’s ongoing focus on the issuance of warning letters to firms marketing fraudulent COVID-19 products, and to manufacturers who have failed to meet certain requirements under applicable FDA Emergency Use Authorizations (EUAs), as well as what manufacturers and health care providers alike can learn from this trend.

Find more items tagged as: Health Care and FDA, Health Care Sector, Policy and Regulatory, Responding to COVID-19
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel